Published in final edited form as:

J Am Chem Soc. 2005 December 7; 127(48): 16921–16934. doi:10.1021/ja054249y.

Temperature dependent studies of NO recombination to heme and heme proteins

Dan Ionascu, Flaviu Gruia, Xiong Ye, Anchi Yu, Florin Rosca, Chris Beck, Andrey Demidov, John S. Olson[†], and Paul M. Champion^{*}

Dept. of Physics and Center for Interdisciplinary Research on Complex Systems, Northeastern University, Boston 02115

Abstract

The rebinding kinetics of NO to the heme iron of myoglobin (Mb) is investigated as a function of temperature. Below 200K, the transition state enthalpy barrier associated with the fastest (~10ps) recombination phase is found to be zero, while a slower geminate phase (~200ps) reveals a small enthalpic barrier ($\sim 3 \pm 1$ kJ/mol). Both of the kinetic rates slow down slightly in the myoglobin (Mb) samples above 200K, suggesting that a small amount of protein relaxation takes place above the solvent glass transition. When the temperature dependence of the NO recombination in Mb is studied under conditions where the distal pocket is mutated (e.g., V68W), the rebinding kinetics lack the slow phase. This is consistent with a mechanism where the slower (~200ps) kinetic phase involves transitions of the NO ligand into the distal heme pocket from a more distant site (e.g., in or near the Xe4 cavity). Comparison of the temperature dependent NO rebinding kinetics of native Mb with that of the bare heme (PPIX) in glycerol reveals that the fast (enthalpically barrierless) NO rebinding process observed below 200K is independent of the presence or absence of the proximal histidine ligand. In contrast, the slowing of the kinetic rates above 200K in MbNO disappears in the absence of the protein. Generally, the data indicate that, in contrast to CO, the NO ligand binds to the heme iron through a “harpoon” mechanism where the heme iron out-of-plane conformation presents a negligible enthalpic barrier to NO rebinding. These observations strongly support a previous analysis (*J. Am. Chem. Soc.* **1988**, 110, 6656) that primarily attributes the low temperature stretched exponential rebinding of MbCO to a quenched distribution of heme geometries. A simple model is presented for MbNO rebinding that explains a variety of experiments, including the dependence of the kinetic amplitudes on the pump photon energy.

Introduction

Myoglobin (Mb) is a small globular heme protein that stores oxygen reversibly in muscle tissue. In addition to O₂, Mb also binds CO and NO, two other diatomic ligands that are involved in a variety of cellular signaling processes when they interact with specific heme proteins^{1–14}. Because these ligands are all photolabile to varying degrees¹⁵, Mb has been used as a convenient sample for studies of the dynamics of diatomic ligand binding to the heme and the associated protein response. Over the years, Mb has become one of the most intensely studied heme proteins, and a wide variety of physical methods^{16–52} have been applied to elucidate its equilibrium, photophysical, and dynamic properties. As such, Mb has become a genuine prototype for the study of heme proteins. Surprisingly, even with the extensive studies

^{*}Champion, P. M.: p.champion@neu.edu, Tel. (617)373-2918, Fax (617)373-2943.

[†]Department of Biochemistry and Cell Biology and the W. M. Keck Center for Computational Biology, Rice University, Houston, Texas 77005

performed on such an apparently simple system, there are still a variety of unanswered questions surrounding the process of diatomic ligand binding.

Kinetic studies of heme systems usually involve ligand photodissociation where a photon is absorbed by the heme group and the bond between the iron and the diatomic ligand is broken. Following this process the diatomic ligand can either return and rebind to the heme (a geminate process) or it can escape to the immediate protein environment (cavities in the protein matrix), pass through fluctuating entry and exit channels, and ultimately out of the protein and into the solvent.

The rebinding of the NO molecule to myoglobin provides an excellent test case for the study of the final binding step(s) involving bond formation at the heme. This is because the geminate rebinding is fast (ps timescale) and nearly (>95%) complete. In contrast, the other diatomics (especially CO) have much smaller geminate amplitudes so that their kinetics are dominated by the ligand escape and re-entry processes. Moreover, the interaction of the NO molecule with heme systems is an important reaction to study because many physiological effects and biological functions of NO have been discovered (neurotransmission^{1,3,4,53}, regulation of vasodilatation^{5,10,53–56}, platelet aggregation⁵⁷, immune response^{58,59}). Due to the ultrafast (ps) nature of the NO rebinding process, and the experimental difficulties associated with temperature dependent studies on such short time scales, there are no reports of any direct experimental determination of the recombination barrier for NO binding to Mb. On the other hand, studies of heme model compounds^{60–64} as well as indirect studies^{28,38,45,65–67} have suggested that the recombination barrier for NO is indeed very small compared with that of CO and O₂.

Because of the relatively slow nature of the CO rebinding process and the stability of the CO adduct, the CO recombination to the heme has been historically the most well-studied heme kinetic process¹⁸. For example, it has been determined^{68,69} that the CO geminate recombination has a weakly non-exponential behavior above 260K that arises from distal pocket protein relaxation on the same timescale (10–100ns) as ligand escape. However, below 200K the recombination kinetics deviates much more dramatically from a simple exponential response. The pioneering experiments performed by Frauenfelder and coworkers^{18,33} have determined that below 200 K the molecular ensemble is kinetically heterogeneous, due to trapped protein conformational substates that bind the CO molecule with different rates. The distribution of protein molecules “frozen” in different conformational states gives rise to an asymmetric distribution of rebinding barriers^{18,24} (in the range 5–15 kJ/mol) and highly stretched non-exponential rebinding kinetics.

We have proposed that one of the key conformational coordinates giving rise to this type of rebinding distribution in heme systems involves the protein induced heme geometry, which can be conveniently (if simplistically) quantified by two moments, the mean iron out-of-heme-plane displacement and its protein induced mean square disorder^{24,70,71}. The non-exponential rebinding behavior appears at low temperatures because the rebinding of the CO molecule to the heme iron occurs on a faster time scale than the interconversion between the protein conformational substates, making the ensemble inhomogeneous with respect to the kinetic measurement. On the other hand, at higher temperatures above 200 K, the interconversion of the protein substates can occur on faster time scales than the CO rebinding process. This leads to kinetic homogeneity within the ensemble and narrows the rate distribution. However, because additional protein relaxation processes also take place at higher temperatures, the free energy rebinding barrier becomes time dependent and can vary on the same timescale as the kinetics. As a result, non-exponential recombination is also observed near room temperature, even though the source of this non-exponential behavior arises from the (homogeneous) relaxation⁶⁹.

The underlying sources of the non-exponential kinetic response in the CO rebinding reactions were determined by using a double pump-pulse kinetic protocol that distinguishes kinetic inhomogeneity from homogeneous relaxation processes^{69;72} and allows the time scale for protein conformational interconversion to be determined⁷². As discussed below, we have recently extended this concept to picosecond timescales⁷³, using a modified protocol, and applied it to the MbNO rebinding reaction.

The recombination of the NO molecule to myoglobin is thought to have two geminate phases near room temperature^{30;74–76}. Following ultrafast photodissociation^{77–81} in aqueous phase near room temperature, the NO molecule geminately recombines within hundreds of picoseconds, suggesting that it has a much smaller effective barrier than CO, where the recombination rate in aqueous solution is $\sim 0.35\text{--}2.5 \times 10^6 \text{ s}^{-1}$ (i.e., $\sim 3.0\text{--}0.4 \mu\text{s}$) depending on the assumed relaxation function^{69;82;83}. Due to the fact that the NO recombination occurs on comparable time scales to the heme/protein relaxation, it has been suggested that the non-exponential MbNO recombination observed near room temperature is due to a time dependent barrier that develops as the photolyzed heme starts relaxing toward its out-of-plane equilibrium conformation^{30;84}. As suggested previously for the CO reaction^{24;85}, those conformations that have the highest rebinding barriers are the ones associated with heme conformations where the iron is further out of the heme plane, so the NO binding reaction might be expected to slow down as time evolves, giving rise to the non-exponential kinetic response. Studies by Magde and coworkers⁸⁶ appear to support this concept by demonstrating that when MbNO loses its proximal histidine at low pH, the non-exponential second phase of the kinetics is eliminated. On the other hand, several kinetic studies involving cobalt substituted heme (where the metal does not undergo an out-of-plane displacement^{87;88}) reveal little change in the kinetic response and suggest that proximal relaxation is unimportant for the NO binding reaction^{38;75;89}. The work presented here indicates that the latter interpretation is correct and that the kinetic changes⁸⁶ involving MbNO at low pH probably arise from a modification of the distal pocket when H64 is protonated and swings out toward the solution^{90–93}.

In addition to temperature-dependent kinetic studies, there have also been experiments in which the influence of the protein motion on ligand rebinding is studied as a function of solvent viscosity^{94–96}. For example, Shreve and coworkers⁹⁶ have carefully studied the effects of glycerol on the amplitudes and rates of the MbNO rebinding reaction at room temperature. Constraints associated with the standard 3-state serial kinetic model were noted, and their analysis suggests that a parallel model is needed to explain the kinetic evolution following MbNO photolysis⁹⁶. Analogous constraints on the standard 3-state serial model are confirmed by the temperature dependent NO recombination and site directed mutant studies reported here. However, we show that if the initial conditions associated with the standard serial model are modified, it can be made consistent with the observations.

The ultrafast kinetics of the MbNO V68 mutants presented here are also consistent with prior studies of MbCO^{27;36;97}, where it has been suggested that the size of the aromatic side chains substituted into position 68 can regulate the ligand pathway and rebinding process. There are four known xenon cavities⁹⁸ within the myoglobin protein matrix and these cavities are thought to play an important role in diatomic ligand rebinding and escape by functioning as transient trapping sites^{49;50;67;99–101}. The distal valine-68 is adjacent to the heme binding site and the mutations V68F and V68W introduce large aromatic side chains (benzyl and tryptophan, respectively) into the distal pocket^{50;97}, completely filling the Xe4 cavity in the case of V68W. It has been shown^{49;50;99} that the geminate phase of MbO₂ and MbCO recombination is dramatically increased upon the V68F and V68W mutations, consistent with the fact that the Xe4 cavity becomes inaccessible in the presence of these large amino acids. Studies involving NO binding to a variety of mutants at position 68 have also been

reported^{28;38;97} and it was suggested that the slow phase of the geminate rebinding involved the return of the ligand from the Xe4 cavity and/or other parts of the interior distal pocket.

The experiments presented here are the first direct kinetic measurements of the temperature dependent NO recombination to the heme iron in Mb. Different heme environments have been examined, including the wild type, the V68 mutants, and the protoheme (with the distal pocket and proximal histidine removed). The novel methodology developed to perform these studies allows us to compare the temperature dependence of the NO recombination in these samples. The temperature dependent data demonstrate that the enthalpic barrier for NO rebinding to the heme is negligible, while the escape of NO from a more distant site (probably the Xe4 cavity) involves a barrier on the order of 3kJ/mol. Other information concerning the relaxation of the distal protein pocket, and the effect of the proximal imidazole bond and heme doming on the NO binding reaction, is also deduced from this work.

Experimental methods

Sample preparation

Horse heart myoglobin (Mb) was purchased from Sigma Chemical Co., used without further purification, and prepared in 75–80% glycerol (v/v) potassium phosphate buffer (pH = 7.8, 0.1 M). The samples were prepared in a glovebox under argon atmosphere to prevent unwanted contamination from molecular oxygen. Under these conditions, 4 μ l of 1 M sodium dithionite ($\text{Na}_2\text{O}_4\text{S}_2$) solution is added to 300 μ l of buffered sample to obtain the deoxy (reduced) Mb species. An additional 2 μ L of 1 M NaNO_2 solution is added to prepare the MbNO adduct. The concentration of protein is chosen so that the sample has an absorbance of about 1 OD at the pump wavelength in a 1 mm pathlength cell. The ferric V68W and V68F mutants were provided by Professor John Olson (Rice University). The preparation of the NO adduct of the mutant samples was done using the same procedure as the wild type (wt) myoglobin sample. Sperm whale Mb, obtained from Sigma Chemical Co., was also carefully compared to horse heart Mb.

Ferric protoporphyrin IX chloride (hemin) was purchased from Porphyrin Products Inc., dissolved in 1M NaOH, and then diluted into glycerol. For typical 80% (v/v) glycerol solutions (glycerol obtained from Acros Organics), the final sample pH is 12. The hemin concentrations for kinetics measurements are typically 50–100 μ M. At higher heme concentration in glycerol solution aggregation is observed, as evidenced by the blue-shift of the Soret and the red-shift of band III in the deoxy sample spectra¹⁰². After flushing with argon, the sample is reduced by addition of a small amount of degassed sodium dithionite solution. The NO adduct is formed from the reduced sample by adding 2 μ L of 1 M NaNO_2 solution. The equilibrium absorption spectra of the samples are obtained using a Hitachi U-3410 spectrophotometer.

Following preparation, the sample is transferred to a homemade cryogenic gastight sample holder under N_2 atmosphere. The sample is in direct contact with the gold-plated copper sample holder to ensure a good heat transfer between the sample and the cryostat cold finger. The sample holder is transferred into the optical cryostat (Janis Research, CCS-150) and, after a 1mTorr vacuum guard is achieved (to minimize heat transfer through the surrounding air), the cooling process is started at a rate of 3 K/min. The temperature is controlled by a model 331E Lakeshore temperature controller and the temperature readings are made by two matched silicon diode temperature sensors, one installed at the control heater and the other one installed at the bottom of the sample holder. After the readings from the two temperature sensors reach the desired temperature, the sample is thermally equilibrated at this temperature for about 30 minutes before the measurements are taken.

Laser system

The laser system used for these experiments consists of a Ti:Sapphire self-mode-locked resonator (MIRA, Coherent, Inc.) that generates tunable (between 700nm and 960 nm) femtosecond pulses (60–100 fs) with a repetition rate of 76 MHz, each containing about 10 nJ of energy.

The blue pulses needed to pump and probe the sample in the Soret absorption band are obtained by doubling the IR light using a 0.25 mm BBO crystal, after which the pulses are chirp compensated by a pair of SF10 prisms down to about 5–8 % of the transform limit time-bandwidth product. After compression, the pulse train is passed through a pulse modulator or a “pulse-picker” (Conoptics, Inc.) to lower the repetition rate of the laser (typically by a factor of 20) in order to help overcome the possibility that at certain lower temperatures the recombination rates might slow down and become competitive with the repetition rate of the laser. The laser system was tuned into resonance with the product state of the studied sample (five coordinated deoxy myoglobin at 433nm and weakly coordinated Fe²⁺PPIX in glycerol at 423 nm).

Signal processing

Due to the small absorption changes that occur when the pump beam excites the sample and the need for a good signal-to-noise ratio, a cascaded lock-in amplifier technique is used where both the pump and probe beams are modulated so that the pump-induced change in the sample transmission can be monitored by detecting a probe modulated signal. The pump beam is modulated by an acousto-optic modulator (Neos Technologies) at 1.5 MHz while the probe beam is modulated by a mechanical chopper working at approximately 800 Hz. The pump beam is passed through an optical delay line with a motorized translation stage (Newport, translation range ~1.2 ns) that controls the pump-probe time delay. Special care was taken in aligning the translation stage using a photodiode and a 50 μ m pinhole system that traveled along with the translation stage and gauged the collimation and parallelism of the laser beam. The beams are collimated into a parallel geometry so that that spatial filtering of the pump beam is possible. The polarizations of the pump and probe pulses are also set to be perpendicular in order to improve the rejection of pump leakage into the detector.

We use the double modulation technique^{80;103} as a third method to reject the pump light leakage into the signal channel. The leakage is especially problematic in low temperature experiments because of the inherent light scattering in the frozen sample, which leads to poor spatial and polarization separation of the pump and probe beams (the polarizations are lost because of multiple scattering and stress induced polarization scrambling).

The dual cascaded lock-in amplifier (LIA) method is configured to detect only the pump-induced and probe-modulated transmission signal. The high frequency lock-in (from which the reference signal for the AOM is derived) is set to have a large bandwidth, so that the low frequency probe modulated signal can pass and be detected by a second lock-in (from which the reference signal for the mechanical chopper is derived). An appropriate choice of LIA time constants and chopping frequencies must be employed in order to minimize the noise level transmitted within the bandwidth of the first LIA. Typical settings for the experiments reported here are: the high frequency lock-in that generates the driving AOM frequency is 1.5MHz with the detection time constant set at $T=100\ \mu$ s (corresponding to a 24 dB/oct equivalent noise bandwidth, ENBW, of $781.2\text{Hz} = 5/64T$ whereas the second, low frequency LIA is set to work at 0.8 kHz with the detection bandwidth set at 300 ms (ENBW=260.4mHz).

Sample scanning

Sample rotation is a common approach that is often used with pulsed laser systems in order to avoid sample deterioration. Also, thermal lensing can give rise to a time varying signal at the pump beam modulation frequency and create an undesirable large background signal, which is also eliminated by spinning the sample. Unfortunately, there are experimental situations (cryogenic studies are one of them) where the sample is required to be stationary.

In order to overcome the problems associated with the stationary sample requirement in low temperature experiments, we developed a novel fast scanning technique¹⁰³ based on an off-axis spinning lens, that creates a common focal point moving in a circle of adjustable radius (1–4 mm). We also found that sample centrifugation (6g) for about 10 minutes significantly reduced the number of cracks within the formed glass. When a suitable sample has been prepared, the radius can be adjusted so that the circular path of the pump and probe beams does not encounter cracks in the sample. The details of the technique will be described elsewhere¹⁰³. Briefly, the methodology allows us to probe stationary samples at cryogenic temperatures and helps to minimize the thermal lensing background signals. Following the sample, a collection lens is used to image the light from the pump and probe beams, after which the pump and probe beams are spatially separated using a pinhole and a polarization analyzer. Even though the double modulation ensures a background free signal without pump leakage, we use the polarization selection to minimize the nonlinear mixing of the modulation frequencies within the detector. This effect occurs due to the nonlinearity of the detector when the average laser power rises above 5 mW, which can create an undesired mixing of the pump and probe modulation frequencies that gives rise to a constant background. The nonlinear mixing was tested by monitoring the DC background signal as a function of the attenuation of the pump and probe beam intensities. The detector used was a biased silicone pin photodiode (Thorlabs, Hamamatsu).

Data analysis

The analysis of the rebinding kinetics is carried out using the maximum entropy method^{104; 105} algorithm. The Maximum Entropy Method (MEM) does not make any pre-analysis assumptions and therefore does not imply any time domain model of choice but rather seeks a representation for the recombination process in the space of decay rates. We can write the survival probability of the unbound ligands as:

$$N(t) = \int_0^{\infty} g(\lambda) e^{-\lambda t} d\lambda$$

where $g(\lambda)$ is the rate distribution of recombination process $N(t)$. When the kinetics stretch over several decades of time, the rate space is conveniently redefined to a logarithmic rate space. The MEM algorithm is used to extract the rate distribution, which for a typical ligand rebinding process, presents several peaks that are usually attributed to particular dynamic processes or conformational substates. To ensure the accuracy of peak estimation the rates are extracted by taking the derivative of the rate distribution. However, for some particular cases the rate distribution does not present distinctly well defined peaks, so we sometimes approximate the resulting rate distribution with a Gaussian least square fit using the Levenberg-Marquardt algorithm¹⁰⁶. For the MbNO kinetics reported here, we use two Gaussians to fit the MEM distribution in order to approximate the relative amplitudes of the two kinetic processes. The errors associated with this procedure can be relatively large and systematically depend upon the separation between the kinetic phases. The errors in the slower phase amplitude increase at lower temperatures because the Gaussian fit to the long time tail of the the time constant distribution begins to deteriorate.

Subsequently, the data are fit using other models, sometimes using the MEM results as the initial guess. We have tried various combinations of fitting functions and we find that an exponential for the fast phase and a stretched exponential for the slow phase does a reasonable job approximating the data. Generally, we use the Levenberg-Marquardt algorithm for nonlinear least squares fitting and we find that the data are not well fit using the standard exponential fitting functions. On the other hand, the use of the MEM algorithm ensures a clean, artifact free approach to the data analysis as demonstrated by earlier studies^{96;105;107}. With this in mind, we emphasize that time dependent rate processes, due to relaxation effects, can not be differentiated from a static distribution of rates simply by applying a MEM analysis (MEM will fit both processes equally well). Additional experimental techniques, such as double pump-pulse kinetic selection⁷², must be used to decide if the ensemble is kinetically inhomogeneous or if barrier relaxations are present.

In the course of these investigations, we also found that the MEM technique can have significant difficulties in extracting the underlying rate distribution when a stretched relaxation is present that cannot be followed over its full dynamic range¹⁰⁸. As a result of this problem, the MEM data analysis yields a “slow” kinetic phase with a rate process that appears to level off below ~100K. This arises from the fact that the experimental arrangement used in these studies can not follow the kinetics beyond ~1200 ps. Because the slow phase kinetics are stretched, the MEM peak does not continue moving towards longer time constants when the slower portion of the decay begins to extend beyond the experimentally accessible time window below ~100K. Therefore, as an alternative fitting procedure below 100K, we utilized an exponential plus a stretched exponential to fit the data. Using this approach, we confirmed that the underlying kinetic time scale of the slow phase continues to increase as the temperature is lowered below 100K, consistent with an Arrhenius barrier on the order of 3 ± 1 kJ/mol. The large error bars reflect the uncertainties associated with the MEM analysis and the limited experimental time window.

Results

The ultrafast studies of MbNO demonstrate that, upon photodissociation, the rebinding kinetics partitions into two phases, with distinctly different temperature dependence. Kinetic studies only at room temperature do not allow an unequivocal distinction of the two phases to be made. This is because at room temperature the two kinetic phases are only separated by a single decade in time, and non-exponential relaxation models can be used to approximate the response within the context of a single kinetic phase. The use of glycerol to control the viscosity at room temperature indicate that two phases are present when MEM analysis is employed⁹⁶, but do not completely rule out alternative fitting models in the context of a single kinetic phase. On the other hand, Figure 1 and Figure 2 demonstrate that one of the phases (the “fast” phase) maintains a nearly constant rate $\sim 10^{11} \text{ s}^{-1}$ over the entire range of studied temperatures, while the other kinetic phase (the “slow” phase $\sim 10^{10} \text{ s}^{-1}$ at $T = 200\text{K}$) slows down as the temperature is lowered. Thus, in Fig. 1 we can clearly differentiate the two phases at low temperature and unambiguously assign them as separate kinetic processes independent of the details of a specific fitting approach.

Because there is a natural break in the kinetic response as a function of temperature near the glass transition temperature ($T_g \sim 180 \text{ K}$ in the 80% glycerol/water solvent), we divide the kinetics into separate temperature ranges as shown in Figure 1. The MEM distributions (translated from rates to time constants; $\tau = k^{-1}$) are shown in the lower part of Fig. 1 where it can be seen that both phases slow down slightly above 200K. Below 200K, the “slow” phase gets slower as the temperature is lowered while the fast phase is independent of temperature. The former observation indicates an enthalpic barrier is associated with the “slow” kinetic process below T_g , while the latter demonstrates that no enthalpic barrier is present for the fast

phase. The temperature dependence above T_g suggests that some type of protein relaxation is taking place as the surrounding solvent softens and melts.

In the region of the solvent glass transition (150K–200K) the optical quality of the samples deteriorates and it appears that a small decrease and recovery of the kinetic rate constants takes place. However, because of the poor optical quality of the samples near T_g , and the associated noise in the kinetic data, we have not included these results in Figure 2. At the lowest temperatures (right hand panel of Fig. 1), the sample is completely frozen and the ligand rebinding can be followed from 130K–30K. In this temperature regime, the slow kinetic phase moves away from the fast phase so that it can be more clearly delineated. For consistency and clarity in the presentation of the kinetic data and the MEM rate distributions, we use the same format as in Fig 1 to present the NO rebinding kinetics of the distal pocket Mb mutant (V68W) and the “bare” heme model compound (PPIX).

In Fig. 1 the temperature dependent rebinding kinetics of MbNO are plotted using the logarithm of the normalized absorption ΔA as a function of logarithmic time. The vertical arrows indicate the direction of the kinetic response as the temperature is lowered. The horizontal arrows indicate how the slow-phase MEM time-constant distribution changes as the temperature is decreased. The MEM time-constant distributions are shown using the same logarithmic time axis that is used for the kinetics, but with a linear amplitude that is given on the right axis.

As can be clearly seen in the left panel of Fig. 1, the recombination kinetics shows anomalous behavior as the temperature is lowered from 290 K to 200 K, becoming faster (rather than slower) as the temperature is decreased toward the solvent glass transition. This anomalous temperature dependence above 200K is observed for both phases (Fig. 2, upper panel and inset). Below 200 K, the slower phase (which appears as a shoulder on the faster phase rate distribution) behaves normally and its rate distribution slows down as the temperature is decreased (see horizontal arrows in the middle and right panels of Fig. 1 and in the Arrhenius plots of Fig. 2). It is noteworthy that the amplitudes of the two phases shown in the lower panel of Fig. 2 remain roughly constant as the temperature is varied. The amplitudes are found by fitting the MEM rate distributions in Fig. 1 using two Gaussian functions, which leads to a relatively large error in the amplitude determination, particularly for the slow phase at lower temperatures (as determined by the increasing difference between the integrated areas of the Gaussian and the MEM distribution).

As can also be seen in Fig. 2, the “fast phase” time constant is independent of temperature below the glass transition. The rate change for the “slow phase” (triangles in upper panel of Fig. 2) leads to an enthalpic barrier of 3 ± 1 kJ/mol between 80K–200K, but appears to level off below 80K. As mentioned in the Experimental Methods section, the leveling off effect is probably an artifact that arises when the long time tail of the non-exponential slow phase kinetic response begins to move beyond the experimental detection window (1.2ns) at the lower temperatures. Separate fits to the data in this region using an exponential for the fast phase and a stretched exponential for the slow phase¹⁰⁸ were therefore used (along with the MEM analysis between 80–200K) to help establish both the errors and the magnitude of the enthalpic barrier for the slow phase.

In Fig. 3 we contrast the room temperature MbNO rebinding kinetics of wild type whale (SW) and horse (HH) along with two of the SW mutants (V68F and V68W). Both a pure aqueous buffer solution and a 75% glycerol/water mixture were used for solvent. The left panel shows the samples in water while the right panel shows the samples in 75% glycerol solution. Note that there are small species differences observable in the kinetic response of the “slow” phase, but these are small effects in comparison to the mutations at V68 so we do not focus on them

here. The native and wt SW Mb have a virtually identical kinetic response and they cannot be differentiated in the figure.

The V68 mutants are important due to the fact that the distal valine-68 is adjacent to the ligand binding site and resides along the pathway to the Xe4 pocket where it can play a potentially important role in determining the overall kinetic barrier to ligand binding^{27;50;99}. There are two major experimental observations to be emphasized in Fig. 3. First, there is a dramatic decrease in the “slow” phase amplitude when the native MbNO is either mutated at V68 (F or W) or if the solvent environment is changed by adding glycerol. Second, and perhaps most important, is the observation that the “fast” phase is nearly independent of both the solvent environment and the sample mutation. The dramatic decrease of the slow phase amplitude when glycerol is added agrees quantitatively with an earlier report by Shreve et al⁹⁶, which showed a systematic decrease in the slow phase amplitude, along with a small increase in the slow phase rate, as the glycerol concentration in the MbNO kinetic samples was increased.

In Fig. 4 we plot the temperature dependent NO recombination kinetics of the V68W mutant. The analysis reveals only a single “fast” phase with an Arrhenius rate behavior shown in Fig. 5. The kinetics are nearly identical to the behavior observed for the “fast” recombination phase found in wild type MbNO, including the weak relaxation and slowing down of the rate as the temperature is increased from 200–290K. Remarkably, the rebinding rate has essentially no temperature dependence in the V68W mutant and the second (“slow”) phase is almost completely suppressed. However, at the lowest temperatures, a slow phase of the kinetic response becomes barely detectible, reflecting the presence of a very small component of this phase (Note that the amplitude of this phase is much smaller than in wild type because the vertical logarithmic axis for the rebinding kinetics in Fig. 4 includes an extra decade compared to Fig. 1). Evidently, the single phase ultrafast kinetic response of the V68W mutant provides a clean experimental look at NO rebinding to the heme from the distal pocket of Mb without complications associated with ligand migration to other parts of the protein.

Similar temperature dependent kinetics measurements have been performed on samples of NO ligated PPIX in glycerol as shown in Fig. 6 and Fig. 7. Again we find that temperature independent rate behavior is observed below the solvent glass transition. The role of the protein environment that surrounds the heme is revealed by the kinetics between 200 and 290K. In contrast to the Mb samples, the kinetics of NO rebinding to bare heme (with water as the fifth ligand) do not slow down as the temperature is increased over this temperature range. Instead, the rates tend to increase (very gradually) with temperature and the Arrhenius plot (see insert in Fig. 7) indicates a small enthalpic barrier ($\sim 0.3\text{kJ/mol}$) in the temperature range above T_g . Given the absence of both the imidazole ligand and the protein material, it is not surprising that the heme in the PPIXNO samples may go through a different conformational relaxation process than observed for MbNO.

Finally, in Fig. 8 we display the Soret band evolution for the MbNO sample at room temperature, obtained using a white light continuum spectrometer¹⁵. Since NO binding to imidazole ligated heme systems can lead to the rupture of the imidazole bond, it is important to clearly establish the state of the proximal histidine-iron bond in the MbNO system (both in equilibrium and immediately following NO photolysis). This issue is important because the timescale for NO rebinding is $\sim 10\text{ps}$ for both the PPIXNO (no imidazole) and the fast component of the MbNO samples. The similarity in the rebinding rates could potentially indicate that the histidine bond is (transiently) absent in the Mb sample. However, as can be seen from the equilibrium and dynamic Soret band difference spectra in Fig. 8, there is a prompt appearance of the five-coordinate (histidine ligated) deoxy Mb spectrum (peaking at 435nm) upon NO photolysis. If the histidine ligand were lost, one would expect to see evidence of a transient bleach near 390nm, analogous to the Soret spectra of the water-ligated PPIXNO, as

shown in the lower portion of Fig. 8. However, the 390nm spectral signature is absent and a normal “hot” (broadened and slightly red-shifted¹⁰⁹) deoxy Soret band at 435nm is clearly present in the early time window. Moreover, femtosecond coherence spectroscopy studies on MbNO have revealed that upon photodissociation, the 220 cm⁻¹ vibrational coherence of the iron histidine stretching mode appears nearly instantaneously (<< 150 fs)^{80;81} further validating that the iron-histidine bond is intact. These results demonstrate that the proximal histidine remains ligated to the heme in Mb, both when NO binds and immediately after it is photodissociated from the heme.

Discussion

Barriers

This work presents the first systematic investigation of the effect of temperature on the ultrafast rebinding of the NO ligand to heme proteins. Several of the main experimental observations are emphasized in Table 1, which displays some of the time constants and barriers for the various samples near room temperature (290K) and just above the solvent glass transition (220K). The faster of the two kinetic phases in MbNO shows a time constant of ~15 ps at 290K that decreases to ~12 ps (i.e., the rate increases) as the temperature is lowered to 220K. This same trend (i.e., a small decrease in the observed kinetic rates as the temperature is raised above T_g) is observed in all of the protein samples studied. Such anomalous kinetic behavior signals that a protein “relaxation” process is taking place in the temperature range above T_g . In contrast, when the temperature is decreased below 220K, the time constant of the fast phase remains fixed, signifying an enthalpic barrier that is negligible for this kinetic process. For the slow phase, the rate decreases when the temperature is lowered below T_g as normally expected, so we report the Arrhenius barrier of the slow phase below T_g , in order to unambiguously decouple it from the relaxation process above T_g .

As can be seen in Table 1, the enthalpic barrier for the slow kinetic phase in MbNO is ~2–4 kJ/mol and the amplitude of this phase is significantly reduced (V68F) or eliminated (V68W) by distal pocket mutants that block the Xe(4) binding site^{50;99}. As a result, we assign this kinetic process to the escape of the NO ligand from a site in or near the Xe4 pocket, following its partial population by hot photolyzed [NO]* ligands (see scheme II below). Within the context of scheme II, the Arrhenius barrier extracted for the slow kinetic phase can be assigned directly to the transition between state “X” (in or near the Xe4 pocket) and state “B” (the heme localized distal pocket). The amplitude of the kinetic phase associated with return from state X can also be increased by choosing a more energetic photon for photolysis (see below). Finally, we note that there is a small increase of the fast phase rate constant when the NO rebinding kinetics of the V68W mutant are compared to wtMb. We attribute this effect to a somewhat smaller ligand accessible volume in the distal pocket (B-state) of the V68W mutant.

Viscosity

In agreement with the work of Shreve et al⁹⁶, we find that the addition of glycerol leads to a systematic reduction of the slow phase amplitude without a significant change in its rate. The lower panel of Fig. 2 also indicates that the slow phase amplitude decreases and the fast phase increases as the temperature is lowered from 290K to 220K. Since the effect of both the addition of glycerol and the decrease of temperature in the 290K to 220K range is to increase the solution viscosity, we suggest that increased viscosity is an important cause of the decrease in the amplitude of the slow kinetic phase. This may be due to the damping of key protein fluctuations, which enable the transitions of the NO ligand from the localized distal pocket (B-state) into the region of the more distant Xe4 cavity (X-state).

On the other hand, we note that glycerol has the potential to perturb the protein structure^{110; 111} and, if a more “open” protein structure is induced by the addition of glycerol, partial occupancy of the Xe4 pocket by glycerol or water may be possible. Near the solvent glass transition at 200K, and below, the amplitudes extracted from the MbNO rebinding kinetics also show variation, but this is probably due to significant systematic error in extracting the amplitudes at the lower temperatures (see Methods section). In addition to the loss of slow phase amplitude when the kinetics move beyond the allowed (~1ns) experimental time range, the errors are increased because the MEM distributions describing the kinetics are not always well fit using 2 symmetric Gaussians.

Relaxation

The slowing down of the kinetics that occurs at higher temperature evidently arises from the initial relaxation of the photolyzed freeze-quenched MbNO protein structure toward the deoxy Mb protein conformation as the temperature is raised above T_g . The effect of this relaxation on the MbNO kinetics is relatively small and is approximated in Table I by using the ratio of observed rates at 290K and 220K. The logarithm of this ratio can be used to approximate the increment in the free energy barrier, ΔG_{relax} , that would be needed in order to account for the anomalous rate decrease with increasing temperature. (The approximation holds exactly for the fast phase, where the enthalpic barrier is zero at 220K). It is noteworthy that the magnitude of the relaxation, as quantified by $\Delta G_{\text{relax}} \sim 0.6 \text{ kJ/mol}$, is nearly the same for all of the protein samples studied. In contrast, the model heme compound (PPIX-NO in glycerol) displays no relaxation process above T_g , even though the fast rebinding time-constant (~8ps) is close to what is observed (~12ps) in the protein prior to the onset of relaxation. The absence of an enthalpic NO rebinding barrier for the fast kinetic phase of MbNO and PPIXNO below 200K suggests that the protein relaxation process observed above 200K is most likely associated with small entropic changes. One possibility is that the increasing degrees of freedom available to the protein at higher temperature lead to a “softening” of the deoxy Mb protein structure, with a concomitant increase in the ligand accessible volume(s) of the distal pocket(s).

It has also been suggested^{30;84} and contested^{38;39;112;113} that evolution in the local heme structure (i.e., time dependent changes in the iron out-of-plane displacement) may be responsible for the non-exponential nature of the geminate kinetic response in MbNO. However, the clear separation of the kinetics into a fast exponential phase and a slower phase at lower temperature, along with the crossover to essentially single exponential (~10ps) behavior when the Xe4 pocket is blocked, suggests that a time dependent geometric change of the heme is an unlikely explanation for either the non-exponential kinetics at room temperature or the small ~0.6 kJ/mol relaxation seen in the MbNO binding reaction. As a result, we do not consider further the possibility of a time dependent heme barrier and k_{BA} is taken to be constant in the kinetic schemes presented below.

In contrast to the NO rebinding results, the temperature dependent kinetic studies of CO binding to both PPIX^{60;114} and Mb display a much more significant decrease in the rate of ligand rebinding as the temperature is increased from 220K to 290K. The ~3kJ/mol ($T > T_g$) relaxation observed in the CO rebinding reaction for PPIXCO¹¹⁴, and the even larger relaxation of ~10kJ/mol for MbCO¹⁰², evidently do arise from changes in the heme geometry (e.g., increased doming) that take place as the protein evolves from the six-coordinate ligand bound conformation to the fully relaxed five-coordinate deoxy conformation^{85;102;115;116}. This view is also consistent with the fact that the enthalpic rebinding barrier for MbCO is much larger (~10 kJ/mol)¹⁰² than for MbNO (~0 kJ/mol) below 220K. Overall, the kinetic results suggest that, when CO binding is used as the kinetic probe, the heme geometric changes induced by the protein relaxation at higher temperatures will be important. The heme structural

relaxation acts to increase the enthalpic rebinding barrier for CO (but not NO) as the solvent/protein/heme system relaxes from the ligand-bound to the ligand-unbound conformation¹¹⁴.

Kinetic inhomogeneity

Understanding why the rebinding barrier at the heme is significantly larger for CO than for NO has been a long standing question^{28;117}. To this we must now add the observation that the low temperature rebinding kinetics for MbCO show extremely non-exponential (i.e., highly “stretched”) behavior¹⁸, while for MbNO (wild type and V68W) the fast phase kinetics are well described by an exponential process. The exponential behavior of the MbNO kinetics is quite surprising because a well-accepted reason for the “stretched” kinetics of MbCO is that the protein conformational substates are “frozen out” on the time-scale of the CO rebinding process^{18;24;71;118}. At higher temperatures (above T_g) the conformational substate interconversion rates begin to exceed the CO rebinding rates so the kinetic inhomogeneities are averaged and the CO rebinding barrier at the heme becomes nearly exponential at 290K. However, since NO has a much faster (four orders of magnitude) rebinding time-scale than CO, one might reasonably expect that the NO kinetics would be much faster than the protein interconversion time-scale, even at room temperature. This should lead to a highly stretched non-exponential response for NO rebinding both above and below T_g . The fact that this is not observed for NO rebinding points to a fundamental difference between the underlying enthalpic barrier distributions associated with the NO and CO rebinding reactions. Temperature derivative spectroscopy studies¹¹⁹ have revealed that the V68 mutations prevent the CO and O₂ movement into the more remote Xe cavities and enhance interactions with the distal histidine. However, if various arrangements of distal pocket amino acid residues and/or ligand docking site configurations were dominant in determining the enthalpic barrier distributions for CO, then one would expect that NO would be affected in nearly the same way (i.e., the fast phase of the NO rebinding kinetics would also show a highly stretched non-exponential decay).

On the other hand, a simple quantitative model for ligand binding to the heme, which focuses on the importance of distributions in the heme geometry²⁴, can directly explain both the different time scales and the exponential vs. non-exponential behavior associated with the NO and CO rebinding reactions. Figure 9 depicts a cartoon model showing the respective transition states for the NO and CO rebinding reactions for two representative protein/heme conformations. We use the phrase “harpoon model” or “doming model” to describe how we visualize the transition states for the NO and CO rebinding reactions, respectively (see Fig. 9). Since NO has an unpaired electron, it is possible to form a transition state bond with the single electron in the d_{z^2} orbital of the high-spin ferrous heme iron atom without first driving the iron into a low-spin configuration. In contrast, the CO molecule has two bonding electrons and the d_{z^2} orbital must be depopulated to reach a viable transition state for binding to the heme. We have suggested previously²⁴ that the enthalpic barrier for such a process can be approximated by $H_P = 1/2 K a^2$, where K is the force constant associated with heme doming (~ 17 N/m) and a is the iron out-of-plane displacement. Thus, what we are suggesting here is that the transition state for NO binding can be formed without pulling the iron into the heme plane. This concept is consistent with a reactant-like transition state for NO binding as discussed by Szabo¹²⁰. This is also consistent with recent calculations that show the intermediate spin state of heme-NO to be a bound state, in contrast to the situation for heme-CO¹¹⁷. These latter calculations provide a more rigorous justification for the recombination of NO to an out-of-plane heme iron.

It is noteworthy that the harpoon model is in complete agreement with the observed NO recombination kinetics on cobalt substituted myoglobin^{38;89}, where the cobalt atom does not move out of the heme plane¹²¹ and a similar NO recombination rate is observed as for the iron based heme^{38;89}. On the other hand, the work presented here indicates that the prior

measurements, demonstrating a loss of the second kinetic phase for MbNO at low pH, probably arise primarily from a modification of the distal pocket and Xe4 cavity (when the distal histidine is protonated at low pH and swings out toward the solution^{90-93;122;123}) rather than from the loss of the proximal histidine⁸⁶.

It would obviously be of great interest to test these ideas further by making similar comparisons between cobalt and iron based heme in the case of CO binding. Unfortunately, CO does not bind to cobalt heme¹²⁴. However, additional kinetic studies³⁸ involving O₂ binding, which should depend to some extent upon the magnitude of heme doming, have shown that the geminate rebinding is much faster (~100ps) for Co substituted heme than for myoglobin with the native iron-based heme. This indicates that heme doming remains as a potentially important control mechanism for the regulation of oxygen binding to Mb and Hb.

The harpoon model predicts that the barrier due to the heme iron out-of-plane displacement is effectively absent for the NO reaction. Moreover, since the protein conformation-induced distribution of iron out-of-plane equilibrium positions is the primary source of the distribution of rebinding barriers for CO (at least in the simple linear electron-nuclear coupling version of the doming model²⁴), this distribution must effectively collapse for NO binding because the reaction is no longer dependent on the heme geometry distribution. This simple idea explains both the dramatic increase in the NO rebinding rate as well as the surprisingly homogeneous (i.e., exponential) nature of its time course.

Kinetic models

When NO is used as the kinetic probe, we are better able to discern the underlying details associated with the distal pocket because the distributions due to the proximal heme geometry that dominate the CO rebinding reaction are eliminated. The presence of the two phases in the MbNO kinetics, along with the experiments on the mutant samples (e.g., V68W), have demonstrated that there are at least two separate states associated with the NO ligand in the distal pocket. One of the states we denote as “B”, in accordance with prior notation, and the other we denote as “X”, which refers to the likelihood that this state corresponds to the NO in or near the Xe(4) cavity. In the B-state, the NO ligand is trapped in the center of the distal pocket, in very close proximity to the heme iron. The state we denote as X may sometimes be referred to as C, or as one of a set of sub-scripted B-states^{49;50;52}. However, the two states we invoke in our kinetic analysis are consistent with the recent calculations of Nutt and Meuwly⁶⁷, where the NO is observed near the center of the distal pocket, in close proximity to the iron, as well as in more extended regions such as in or near the Xe(4) cavity.

Two fundamentally different models that can potentially explain the observed kinetics of MbNO in terms of the B and X states are shown below as scheme I and scheme II.

The first model, denoted as scheme I, uses a coarse-grained kinetic inhomogeneity to explain the two observed phases. The interconversion between two protein conformations is taken to be slow compared to the rebinding reaction rate. Within this scheme, the fast and slow kinetic phases are associated with the two protein conformations and the populations of the two conformers are allowed to vary in order to account for the differing amplitudes when the distal pocket is mutated or the glycerol concentration is changed.

The second model (scheme II) is kinetically homogeneous and has been previously discussed by Shreve et al.⁹⁶, but with different assignments for the various states (see below). Scheme II invokes a distribution of initial conditions between the B and X states, which is created as the hot photolyzed NO fragment cools and comes to equilibrium. (Here, we have used γ to denote, in the most general sense, the photolysis and redistribution of the ligand in Scheme II instead of using explicit state-specific rates $k_{\gamma X}$ and $k_{\gamma B}$. A more detailed version of the ligand

redistribution in Scheme II is given in Fig. 10b, where we explicitly show the initially excited electronic state of Mb). A distribution of initial conditions (B_0 and X_0) is used instead of placing all of the initial population in state B (as is done in the standard 3-state serial model). The distribution of initial population between B_0 and X_0 is necessary in order to decouple the observed rates and amplitudes, as observed experimentally (i.e., V68 mutation or glycerol concentration changes the relative amplitudes without significantly affecting the rates). This latter issue was stressed by Shreve et al.⁹⁶ in their analysis of the glycerol-dependent kinetic amplitudes, and we are in accord with their basic conclusions on this point. However, since the V68 mutant results indicate that state X is associated with the more distant Xe4 site, we consider it unlikely that the NO ligand can make a transition directly from X to the bound state A without first passing through the more localized distal pocket state B. Thus, we do not believe that the two states represent B-state roto-isomers as previously suggested⁹⁶ and to be consistent with an assignment for X in or near the Xe4 pocket, we set $k_{XA} = 0$ in the final working expressions for the homogeneous model.

In order to interpret the observed kinetic rates, in terms of the fundamental rates shown in scheme II, we first express the general solution for the kinetic time course of the individual state populations as:

$$B(t) = \frac{1}{\sqrt{D}} [k_{XB}X_0 - B_0(k_{BA} + k_{BX} + K_-)]e^{k_+t} - \frac{1}{\sqrt{D}} [k_{XB}X_0 - B_0(k_{BA} + k_{BX} + K_+)]e^{k_-t} \quad (1a)$$

$$X(t) = \frac{1}{\sqrt{D}} [k_{BX}B_0 - X_0(k_{XA} + k_{XB} + K_-)]e^{k_+t} - \frac{1}{\sqrt{D}} [k_{BX}B_0 - X_0(k_{XA} + k_{XB} + K_+)]e^{k_-t} \quad (1b)$$

Thus, if we use the normalization condition ($A+B+X=1$), the expression for the observed kinetic time course of the unbound population can be written as:

$$1 - A(t) = \frac{1}{\sqrt{D}} [B_0(k_{BA} + K_+) + X_0(k_{XA} + K_+)]e^{k_-t} - \frac{1}{\sqrt{D}} [B_0(k_{BA} + K_-) + X_0(k_{XA} + K_-)]e^{k_+t} \quad (1c)$$

where the other variables in Eq. 1 are given by:

$$D = (k_{BA} + k_{XA} + k_{BX} + k_{XB})^2 - 4(k_{BA}k_{XA} + k_{BA}k_{XB} + k_{XA}k_{BX}) \quad (2a)$$

$$K_{\pm} = \frac{1}{2} \left[-(k_{BA} + k_{XA} + k_{BX} + k_{XB}) \pm \sqrt{D} \right] \quad (2b)$$

and the quantities X_0 and B_0 correspond to the initial populations of the X and B states, respectively. The quantities $K_{\pm}$ are the two observed rates. As can be seen from Eq 1c, a scheme II model with an initial condition of $B_0 = 1$ does not allow for the decoupling of the observed rates from the amplitudes (i.e., the only way to change the amplitudes is by changing the rates). On the other hand, when the possibility of a distribution in the initial photolyzed populations between X_0 and B_0 is acknowledged, the amplitudes can be altered by simply changing the initial population distribution.

The mutation studies help us to simplify scheme II and Eq. 1 because we can set $k_{XA} = 0$ and, since the fast rate changes only slightly when the transition to and from X is eliminated by the V68W mutation (see Table 1), we can also infer that $k_{BA} \gg k_{BX}$, k_{XB} . Expansion of the expression for $\sqrt{D}$ followed by simplification of the rate expressions under the above conditions leads directly to:

$$1 - A(t) = I(t) = B_0 e^{-k_{BA}t} + X_0 e^{-k_{XB}t} \quad (3)$$

so that in scheme II, with $k_{BA} \gg k_{BX}$, k_{XB} and $k_{XA} = 0$, the experimentally measured rates and amplitudes directly translate to the fundamental rates and initial populations. In the current application for MbNO, the rates of the two observed kinetic phases differ by at least an order of magnitude (10ps and 200ps) so the $k_{BA} \gg k_{XB}$ condition is confirmed.

The fact that the observed “fast” (k_{BA}) and “slow” (k_{XB}) rates differ by a factor of 10–20 can also be cross-checked independently by considering the following simple approximation. The $\sim 3\text{kJ/mol}$ enthalpic barrier for k_{XB} accounts for roughly a factor of 6 reduction with respect to k_{BA} at 200K (since k_{BA} has no enthalpic barrier). In addition, the ratio of the ligand accessible volume of the Xe4 pocket to that of the B-state distal pocket can be calculated¹²⁵ and used to estimate an entropic reduction in the relative transition rates of ~ 2.5 (using equivalent transition state entropies). This crude approximation yields an overall ratio for $k_{BA}/k_{XB} \sim 15$, which is very close to what is observed experimentally.

Kinetic selection

In order to more clearly differentiate between the inhomogeneous scheme I and the homogeneous scheme II, we have performed double pump-pulse kinetic selection experiments⁷² on MbNO. The protocol for performing such experiments on ultrafast timescales is significantly different¹²⁶ than that used previously for the nanosecond kinetic experiments⁷². However, the basic logic is the same. Namely, for an ensemble of two slowly interconverting conformers with fast and slow ligand rebinding kinetics, a second delayed pump pulse can be temporally positioned to kinetically select the fast rebinding subpopulation so that its kinetics can be extracted and compared to the kinetics of the full ensemble (as measured using a single pump pulse). When such experiments are performed, the delay between the two pump pulses can, in principle, be extended until it is longer than the interconversion time between the kinetically distinct conformers, so that the kinetics of the selected subpopulation becomes the same as that of the full ensemble. Such experiments were performed on MbNO with delay times between the pump pulses of 10ps to 150ps¹²⁶. In no case did the observed kinetics of the selected subpopulation deviate from that of the full ensemble. Thus, we conclude that the inhomogeneous Scheme I above can be eliminated as a possible explanation of the MbNO rebinding kinetics.

Initial populations

Within Scheme II, we find that the hot photolyzed NO fragment must bifurcate between two possible distal sites (B and X) and that the amount of NO that deposits into the X site is depends upon distal pocket mutations (V68W or V68F), viscosity (glycerol concentration), and the energy of the photon used for photolysis. In Figure 10 we delineate scheme II in more detail, showing the distal pocket architecture (panel a), the kinetic model (panel b), and the result of room temperature kinetics measurements¹⁵ on MbNO as a function of pump-pulse wavelength (panel c). Since the experimental measurement of the MbNO kinetics effectively reads out the fundamental rates, the observed “fast” and “slow” kinetic rate constants correspond to heme rebinding (k_{BA}) and the transition from the “X” site into B (k_{XB}), respectively. The distribution of initial conditions is found directly from the measured amplitudes so that from panel c in Fig. 10, we see that the relative amplitude of the slow phase is increased when the pump photons become more energetic as the pump wavelength moves to the blue. (The details of the fits to the data can be found in Table 2; note that the two probe wavelengths in Fig. 10c separately follow the bleach and anti-bleach signals and yield the same results, as expected for a two electronic state kinetic process).

The results shown in Fig. 10c are consistent with the idea that a more energetic photon will impart more kinetic energy to the photolyzed NO fragment, making it more probable that the NO finds its way to the more distant distal site “X”. Since the observed kinetic amplitude for

the slow phase directly yields the initial amplitude, X_0 (i.e., the amount of photolyzed NO that starts from X), the data indicate that the bifurcation ratio X_0/B_0 is about 1.5 when 400nm light is used for photolysis and drops to about 0.8 when 580nm light is used (see Table 2).

Comparison to CO

In comparison to NO, the amplitude of CO geminate rebinding is much smaller at room temperature ($\sim 5\%$) so that $k_{BX} \gg k_{BA}$ and most of the initially hot CO that ends up in or near the Xe4 site (or other “X” sites) eventually escapes from the protein. The librational and translational disorder associated with the initially photodissociated diatomic molecules might make these transient CO species difficult to detect using either time resolved infrared or x-ray techniques. However, significant CO population has been observed¹²⁷ in the Xe(4) pocket of the L29F mutant and in the YQR triple mutant¹²⁸, but not in the native protein on ps timescales. Unfortunately, the time resolved x-ray work^{127;129} only rarely^{130;131} quantifies the absolute CO x-ray scattering intensity, so it is possible that disorder of the dissociated ligand makes it difficult to detect CO in the Xe4 cavity of wt Mb. Moreover, transference of the dynamic information obtained in the time resolved x-ray studies to the solution phase implicitly assumes that the protein dynamics are independent of the differences between the crystal and solution environments. Early Raman spectroscopic studies that focus on this issue^{132;133} suggest that there may be significant differences in the CO escape from crystalline Mb when compared to Mb in solution. The significantly retarded approach of MbCO to photostationary equilibrium in the crystalline state, along with the very slow CO rebinding observed in the crystal¹³² (cf. Fig. 4 of ref. 132 and surrounding discussion), suggest that optical “pumping” may be taking place in the crystal environment whereas in solution a more rapid equilibration of CO within the protein matrix is taking place. One must also consider the possibility that NO and CO behave differently as they migrate through the protein. However, it remains possible that the time resolved x-ray studies of MbCO crystals do actually reflect the spatial and temporal trajectories of NO within solution phase Mb. In that case, the photolyzed CO evidently does not rapidly partition into the Xe4 cavity and the kinetic state “X” must then be interpreted as a docking site near this cavity that is somehow blocked or perturbed by the V68 mutations.

We also note that recent work on the kinetics of CO binding to Mb and a series of PPIX model compounds¹⁰² has found the proximal heme barrier (e.g., due to heme doming) to be $H_P \sim 10\text{kJ/mol}$. In addition to this heme specific term, the overall barrier for CO rebinding to Mb also includes a roughly equivalent distal pocket barrier, $H_D \sim 10\text{kJ/mol}$, that is absent in the PPIXCO model systems¹⁰². Thus, a question arises concerning the absence of the distal barrier in the case of NO rebinding. While the “harpoon” model for NO rebinding naturally explains the absence of the proximal heme barrier, and the decoupling of the protein conformational substates, it does not specifically address the issue of why there is no significant distal rebinding barrier observed for NO.

One possibility is that the distal barrier takes time to develop. Prior work on the geminate rebinding kinetics of MbCO has strongly indicated^{69;105} that distal pocket barrier relaxation takes place on nanosecond time scales (following the much faster ps heme relaxation). Consistent with this scenario, the NO rebinding to the heme may take place prior to the development of the distal pocket barrier. One potential source of the distal barrier is histidine 64, which may need to be displaced in order for the CO ligand to bind in its upright position^{134;135}. If the relaxation of the distal histidine to a position which blocks the distal binding site takes on the order of nanoseconds or longer, this would be consistent with the various kinetic observations. Alternatively, the bent nature of the Fe-NO ligand geometry (in contrast to the linear Fe-CO geometry) would also be a simple way to explain the lack of the distal rebinding barrier for NO (i.e., with the bent conformation, it may not be necessary to displace the distal histidine 64 residue^{97;136}).

Barrier relaxation for k_{XB}

Finally, we would like to draw attention to the fact that, in Figure 10b, we have indicated that the transition from state X to state B appears to involve a process with a time dependent free energy barrier, i.e., the rate $k_{XB}(t)$ is shown explicitly to have time dependence. We suggest this because of the distinctly stretched character of the slow phase kinetics in MbNO, which corresponds to the transition from X to B. In addition, we have considered the recent state-specific kinetics of the MbNO reaction intermediates obtained using time resolved infrared techniques^{52,137}. Our analysis suggests that a kinetic scheme such as outlined in Fig. 10b offers a self-consistent explanation for both the vibrationally specific (IR)⁵² and the electronically specific (optical) measurements presented here.

We note that scheme II (Fig 10b) differs from the recent model proposed on the basis of IR kinetics measurements alone⁵². The 4-state IR model⁵² (A, B₀, B₁, B₂) can be made equivalent to the 3-state model (A, B, X) presented here, if the ~2% IR minority state, B₂, is neglected and the rebinding to A is taken to proceed through B₀ rather than B₁ (i.e., B₀ and B₁ in ref ⁵² become, respectively B and X in scheme II). The mutant studies and double pump pulse kinetics reported here solidify these assignments. Moreover, a simulation of the measured IR population decays⁵² indicates that scheme II (Fig. 10b) can yield equivalent fits to the IR data when compared to the fits using the model suggested by the IR data alone⁵².

Conclusion

This work presents the first comprehensive measurements of the temperature dependent NO rebinding kinetics of Mb and its distal pocket mutants. Rebinding of NO to protoporphyrin IX in glycerol is also studied so that the effect of the surrounding protein material can be assessed. We conclude that the two observed kinetic phases observed in Mb correspond to fast rebinding of NO to heme from a localized state ("B") near the heme ($k_{BA} \sim 10$ ps) and a slower (time dependent) transition ($\langle k_{XB}(t) \rangle \sim 200$ ps) that monitors the motion of the ligand from a somewhat more distant site (e.g., in or near the Xe4 pocket) to the localized B-state. The fast transition for NO has no enthalpic barrier and shows no evidence for the existence of protein conformational substates, in stark contrast to what is observed for CO binding to Mb. This observation can be easily explained if the transition state for NO binding is reactant-like and the extra unpaired electron on the NO molecule "harpoons" the heme iron atom without it having to be driven into the heme plane by thermal fluctuations. Moreover, the exponential nature of the dominant (10ps) NO rebinding process shows that the NO reaction is decoupled from the protein conformational substates. This strongly implies that the non-exponential kinetics observed for CO rebinding at low temperatures¹⁸ arises primarily from the quenched distribution of heme iron out-of-plane displacements²⁴. The temperature dependent kinetics also reveal that the slow transition has a small enthalpic barrier (~3kJ/mol), which is self-consistent with the relative time constants of the two kinetic phases when the respective volumes of the distal pocket and the Xe4 cavity are considered. Finally, for MbNO, the relative amplitudes of the fast and slow kinetic response depend upon distal mutation, viscosity, and the photon excitation wavelength. In contrast to the mutation and viscosity perturbations, which suppress the slow phase, more photon energy in the photolysis step leads to an increased probability that the NO ligand will find its way to a more distant site "X" (in or near the Xe4 cavity).

Acknowledgements

This work was supported by NIH (DK035090) and NSF (DMB 0211816) to PMC and by NIH grants GM 35649 and HL 47020 to JSO. JSO is also supported by Robert A. Welch Foundation grant C-0612.

References

1. Moncada S, Palmer RMJ, Higgs EA. *Pharmacol.Rev* 1991;43:109–142. [PubMed: 1852778]
2. Marletta MA. *J.Biol.Chem* 1993;268:12231–12234. [PubMed: 7685338]
3. Dawson TM, Dawson VL, Snyder SH. *Molecular Mechanisms of Nitric-Oxide Actions in the Brain* 1994:76–85.
4. Dawson TM, Snyder SH. *J.Neurosci* 1994;14:5147–5159. [PubMed: 8083727]
5. Moncada S. *J.Hypertens* 1994;12:S35–S39.
6. Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM, Snyder SH. *Nature* 1995;378:383–386. [PubMed: 7477374]
7. Shelver D, Kerby RL, He Y, Roberts GP. *Proc.Natl.Acad.Sci.U.S.A* 1997;94:11216–11220. [PubMed: 9326589]
8. Gow AJ, Stamler JS. *Nature* 1998;391:169–173. [PubMed: 9428761]
9. Zhao Y, Brandish PE, Ballou DP, Marletta MA. *Proc.Natl.Acad.Sci.U.S.A* 1996;96:14753–14758. [PubMed: 10611285]
10. Ignarro LJ, Cirino G, Casini A, Napoli C. *J.Cardiovasc Pharmacol* 1999;34:879–886. [PubMed: 10598133]
11. Wardrop SL, Watts RN, Richardson DR. *Biochemistry* 2000;39:2748–2758. [PubMed: 10704227]
12. Kumazaki S, Nakajima H, Sakaguchi T, Nakagawa E, Shinohara H, Yoshihara K, Aono S. *J.Biol.Chem* 2000;275:38378–38383. [PubMed: 10978334]
13. Uchida T, Ishikawa H, Ishimori K, Morishima I, Nakajima H, Aono S, Mizutani Y, Kitagawa T. *Biochemistry* 2000;39:12747–12752. [PubMed: 11041838]
14. Fogel U, Merx MW, Godecke A, Decking UKM, Schrader J. *Proc.Natl.Acad.Sci.U.S.A* 2001;98:735–740. [PubMed: 11136228]
15. Ye X, Demidov AA, Champion PM. *J.Am.Chem.Soc* 2002;124:5914–5924. [PubMed: 12010067]
16. Perutz MF. *Nature* 1970;228:726–739. [PubMed: 5528785]
17. Tamura M, Asakura T, Yonetani T. *Biochim.Biophys.Acta* 1973;295:467–479. [PubMed: 4349327]
18. Austin RH, Beeson KW, Eisenstein L, Frauenfelder H, Gunsalus IC. *Biochemistry* 1975;14:5355–5373. [PubMed: 1191643]
19. Spertalian K, Lang G, Yonetani T. *Biochim.Biophys.Acta* 1976;428:281–290. [PubMed: 1276159]
20. Uyeda M, Peisach J. *Biochemistry* 1981;20:2028–2035. [PubMed: 7225371]
21. Caughey WS, Shimada H, Choc MG, Tucker MP. *Proc.Natl.Acad.Sci.U.S.A* 1981;78:2903–2907. [PubMed: 6942409]
22. Lamar GN, Deropp JS, Latosgrzynski L, Balch AL, Johnson RB, Smith KM, Parish DW, Cheng RJ. *J.Am.Chem.Soc* 1983;105:782–787.
23. Ansari A, Berendzen J, Braunstein D, Cowen BR, Frauenfelder H, Hong MK, Iben IET, Johnson JB, Ormos P, Sauke TB, Scholl R, Schulte A, Steinbach PJ, Vittitow J, Young RD. *Biophys.Chem* 1987;26:337–355. [PubMed: 3607234]
24. Srajer V, Reinisch L, Champion PM. *J.Am.Chem.Soc* 1988;110:6656–6670.
25. Petrich JW, Martin JL. *Chem.Phys* 1989;131:31–47.
26. Magliozzo RS, Peisach J. *Biochemistry* 1993;32:8446–8456. [PubMed: 8395204]
27. Egeberg KD, Springer BA, Sligar SG, Carver TE, Rohlfs RJ, Olson JS. *J.Biol.Chem* 1990;265:11788–11795. [PubMed: 2114403]
28. Carver TE, Rohlfs RJ, Olson JS, Gibson QH, Blackmore RS, Springer BA, Sligar SG. *J.Biol.Chem* 1990;265:20007–20020. [PubMed: 2246277]
29. Young RD, Frauenfelder H, Johnson JB, Lamb DC, Nienhaus GU, Philipp R, Scholl R. *Chem.Phys* 1991;158:315–327.
30. Petrich JW, Lambry JC, Kuczera K, Karplus M, Poyart C, Martin JL. *Biochemistry* 1991;30:3975–3987. [PubMed: 2018766]
31. Genberg L, Richard L, Mclendon G, Miller RJD. *Science* 1991;251:1051–1054. [PubMed: 1998121]
32. Miller RJD. *Annu.Rev.Phys.Chem* 1991;42:581–614. [PubMed: 1747193]

33. Steinbach PJ, Ansari A, Berendzen J, Braunstein D, Chu K, Cowen BR, Ehrenstein D, Frauenfelder H, Johnson JB, Lamb DC, Luck S, Mourant JR, Nienhaus GU, Ormos P, Philipp R, Xie AH, Young RD. *Biochemistry* 1991;30:3988–4001. [PubMed: 2018767]
34. Frauenfelder H, Sligar SG, Wolynes PG. *Science* 1991;254:1598–1603. [PubMed: 1749933]
35. Nienhaus GU, Frauenfelder H, Parak F. *Physical Review B-Condensed Matter* 1991;43:3345–3350.
36. Quillin ML, Arduini RM, Olson JS, Phillips GN Jr. *J.Mol.Biol* 1993;234:140–155. [PubMed: 8230194]
37. Lim M, Jackson TA, Anfinrud PA. *Proc.Natl.Acad.Sci.U.S.A* 1993;90:8302.
38. Ikeda-Saito M, Dou Y, Yonetani T, Olson JS, Li TS, Regan R, Gibson QH. *J.Biol.Chem* 1993;268:6855–6857. [PubMed: 8463211]
39. Li HY, Elber R, Straub JE. *J.Biol.Chem* 1993;268:17908–17916. [PubMed: 8349675]
40. Sage JT, Ivanov D, Keim M, Powell JR, Asher SA, Champion PM. *Biophys.J* 1994;66:A 271.
41. Zhu LY, Sage JT, Champion PM. *Science* 1994;266:629–632. [PubMed: 7939716]
42. Deak J, Richard L, Pereira M, Chui HL, Miller RJD. *Methods Enzymol* 1994;232:322–360. [PubMed: 8057868]
43. Springer BA, Sligar SG, Olson JS, Phillips GN Jr. *Chem.Rev* 1994;94:699–714.
44. Carlson ML, Regan R, Elber R, Li HY, Phillips GN, Olson JS, Gibson QH. *Biochemistry* 1994;33:10597–10606. [PubMed: 8075059]
45. Olson JS, Phillips GN Jr. *J.Biol.Chem* 1996;271:17593–17596. [PubMed: 8698688]
46. Sage, JT.; Champion, PM. *Comprehensive Supramolecular Chemistry*. Oxford, U. K.: Pergamon; 1996. Chapter 6; p. 171-218.
47. Sage JT, Jee W. *J.Mol.Biol* 1997;274:21–26. [PubMed: 9398512]
48. Godbout N, Havlin R, Salzmann R, Debrunner PG, Oldfield E. *J.Phys.Chem.A* 1998;102:2342–2350.
49. Scott EE, Gibson QH, Olson JS. *J.Biol.Chem* 2001;276:5177–5188. [PubMed: 11018046]
50. Nienhaus K, Deng PC, Olson JS, Warren JJ, Nienhaus GU. *J.Biol.Chem* 2003;278:42532–42544. [PubMed: 12907676]
51. Sage, JT. *Encyclopedia of Supramolecular Chemistry*. New York: Marcel Dekker, Inc.; 2004. p. 636-644.
52. Kim S, Lim M. *J.Am.Chem.Soc* 2005;127:8908–8909. [PubMed: 15969541]
53. Moncada S, Higgs A. *N.Engl.J.Med* 1993;329:2002–2012. [PubMed: 7504210]
54. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF. *Proc.Natl.Acad.Sci.U.S.A* 1990;87:3629–3632. [PubMed: 2333306]
55. Kilbourn RG, Gross SS, Lodato RF, Adams J, Levi R, Miller LL, Lachman LB, Griffith OW. *J.Natl.Cancer Inst* 1992;84:1008–1016. [PubMed: 1376778]
56. Bredt DS, Snyder SH. *Annu.Rev.Biochem* 1994;63:175–195. [PubMed: 7526779]
57. Pawloski JR, Hess DT, Stamler JS. *Nature* 2001;409:622–626. [PubMed: 11214321]
58. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB. *Cancer Res* 1995;55:5272–5275. [PubMed: 7585587]
59. Fiorucci S, Antonelli E, Distrutti E, Del Soldato P, Flower RJ, Clark MJP, Morelli A, Perretti M, Ignarro LJ. *Proc.Natl.Acad.Sci.U.S.A* 2002;99:15770–15775. [PubMed: 12427966]
60. Miers JB, Postlewaite JC, Zyung T, Chen S, Roemig GR, Wen X, Dlott DD, Szabo A. *J.Chem.Phys* 1990;93:8771–8776.
61. Miers JB, Postlewaite JC, Cowen BR, Roemig GR, Lee IYS, Dlott DD. *J.Chem.Phys* 1991;94:1825–1836.
62. Traylor TG, Magde D, Taube DJ, Jongeward KA, Bandyopadhyay D, Luo JK, Walda KN. *J.Am.Chem.Soc* 1992;114:417–429.
63. Traylor TG, Magde D, Marsters J, Jongeward K, Wu GZ, Walda K. *J.Am.Chem.Soc* 1993;115:4808–4813.
64. Grogan TG, Bag N, Traylor TG, Magde D. *J.Phys.Chem* 1994;98:13791–13769.
65. Gibson QH, Olson JS, Mckinnie RE, Rohlfis RJ. *J.Biol.Chem* 1986;261:228–239.

66. Gibson QH, Regan R, Olson JS, Carver TE, Dixon B, Pohajdak B, Sharma PK, Vinogradov SN. *J.Biol.Chem* 1993;268:16993–16998. [PubMed: 8349589]
67. Nutt DR, Meuwly M. *Chemphyschem* 2004;5:1710–1718. [PubMed: 15580931]
68. Lambright DG, Balasubramanian S, Boxer SG. *Chem.Phys* 1991;158:249–260.
69. Tian WD, Sage JT, Srajer V, Champion PM. *Phys.Rev.Lett* 1992;68:408–411. [PubMed: 10045884]
70. Srajer V, Schomacker KT, Champion PM. *Phys.Rev.Lett* 1986;57:1267–1270. [PubMed: 10033400]
71. Champion PM. *J.Raman Spectrosc* 1992;23:557–567.
72. Tian WD, Sage JT, Champion PM, Chien E, Sligar SG. *Biochemistry* 1996;35:3487–3502. [PubMed: 8639499]
73. Yu A, Ye X, Ionascu D, Cao W, Champion PM. 2005to be submitted
74. Cornelius PA, Hochstrasser RM, Steele AW. *J.Mol.Biol* 1983;163:119–128. [PubMed: 6834427]
75. Gibson QH, Regan R, Elber R, Olson JS, Carver TE. *J.Biol.Chem* 1992;267:22022–22034. [PubMed: 1429552]
76. Shreve AP, Franzen S, Simpson MC, Woodruff WH, Dyer RB. *Biophys.J* 1997;72:A424.
77. Martin JL, Migus A, Poyart C, Lecarpentier Y, Antonetti A, Orszag A. *Biochem.Biophys.Res.Commun* 1982;107:803–810. [PubMed: 7138519]
78. Anfinrud PA, Han C, Hochstrasser RM. *Proc.Natl.Acad.Sci.U.S.A* 1989;86:8387–8391. [PubMed: 2554314]
79. Franzen S, Bohn B, Poyart C, Martin JL. *Biochemistry* 1995;34:1224–1237. [PubMed: 7827072]
80. Rosca F, Kumar ATN, Ionascu D, Sjodin T, Demidov AA, Champion PM. *J.Chem.Phys* 2001;114:10884–10898.
81. Champion PM, Rosca F, Ionascu D, Cao WX, Ye X. *Faraday Discuss* 2004;127:123–135. [PubMed: 15471342]
82. Henry ER, Sommer JH, Hofrichter J, Eaton WA. *J.Mol.Biol* 1983;166:443–451. [PubMed: 6854651]
83. Lambright DG, Balasubramanian S, Decatur SM, Boxer SG. *Biochemistry* 1994;33:5518–5525. [PubMed: 8180174]
84. Meuwly M, Becker OM, Stote R, Karplus M. *Biophys.Chem* 2002;98:183–207. [PubMed: 12128198]
85. Srajer V, Champion PM. *Biochemistry* 1991;30:7390–7402. [PubMed: 1854744]
86. Duprat AF, Traylor TG, Wu GZ, Coletta M, Sharma VS, Walda KN, Magde D. *Biochemistry* 1955;34:2634–2644. [PubMed: 7873545]
87. Hoard JL, Scheidt WR. *Proc.Natl.Acad.Sci.U.S.A* 1973;70:3919–3922. [PubMed: 4521218]
88. Fermi G, Perutz MF, Dickinson LC, Chien JCW. *J.Mol.Biol* 1982;155:495–505. [PubMed: 7086900]
89. Kholodenko Y, Gooding EA, Dou Y, Ikeda-Saito M, Hochstrasser RM. *Biochemistry* 1999;38:5918–5924. [PubMed: 10231545]
90. Morikis D, Champion PM, Springer BA, Sligar SG. *Biochemistry* 1989;28:4791–4800. [PubMed: 2765511]
91. Sage JT, Morikis D, Champion PM. *Biochemistry* 1991;30:1227–1237. [PubMed: 1991102]
92. Sage JT, Morikis D, Li PS, Champion PM. *Biophys.J* 1992;61:1041–1044. [PubMed: 1581497]
93. Yang F, Phillips GN Jr. *J.Mol.Biol* 1996;256:762–774. [PubMed: 8642596]
94. Ansari A, Jones CM, Henry ER, Hofrichter J, Eaton WA. *Science* 1992;256:1796–1798. [PubMed: 1615323]
95. Kleinert T, Doster W, Leyser H, Petry W, Schwarz V, Settles M. *Biochemistry* 1998;37:717–733. [PubMed: 9425096]
96. Shreve AP, Franzen S, Simpson MC, Dyer RB. *J.Phys.Chem.B* 1999;103:7969–7975.
97. Quillin ML, Li TS, Olson JS, Phillips GN, Dou Y, Ikeda-saito M, Regan R, Carlson M, Gibson QH, Li HY, Elber R. *J.Mol.Biol* 1995;245:416–436. [PubMed: 7837273]
98. Tilton RF Jr, Kuntz ID Jr, Petsko GA. *Biochemistry* 1984;23:2849–2857. [PubMed: 6466620]
99. Dantsker D, Samuni U, Friedman AJ, Yang M, Ray A, Friedman JM. *J.Mol.Biol* 2002;315:239–251. [PubMed: 11779242]
100. Lamb DC, Nienhaus K, Arcovito A, Draghi F, Miele AE, Brunori M, Nienhaus GU. *J.Biol.Chem* 2002;277:11636–11644. [PubMed: 11792698]

101. Tetreau C, Blouquit Y, Novikov E, Quiniou E, Lavalette D. *Biophys.J* 2004;86:435–447. [PubMed: 14695286]
102. Ye X, Yu AC, Georgiev GY, Gruia F, Ionascu D, Cao WX, Sage JT, Champion PM. *J.Am.Chem.Soc* 2005;127:5854–5861. [PubMed: 15839683]
103. Ionascu D, Gruia F, Rosca F, Yu A, Champion PM. 2005to be submitted
104. Skilling J, Bryan RK. *Monthly notices of the Royal Astronomical Society* 1984;211:111-&..
105. Kumar ATN, Zhu L, Christian JF, Demidov AA, Champion PM. *J.Phys.Chem.B* 2001;105:7847–7856.
106. Press, WH.; Teukolsky, SA.; Vetterling, WT.; Flannery, BP. *Numerical Recipes in C*. 2 ed.. Cambridge University Press; 1992.
107. Steinbach PJ. *Biophys.J* 1996;70:1521–1528. [PubMed: 8785309]
108. Ionascu, D. PhD Thesis, Northeastern University. 2005.
109. Ye X, Demidov A, Rosca F, Wang W, Kumar A, Ionascu D, Zhu L, Barrick D, Wharton D, Champion PM. *J.Phys.Chem.A* 2003;107:8156–8165.
110. Sivakolundu SG, Mabrouk PA. *J.Am.Chem.Soc* 2000;122:1513–1521.
111. Sivakolundu SG, Mabrouk PA. *Journal Of Biological Inorganic Chemistry* 2003;8:527–539. [PubMed: 12764601]
112. Schaad O, Zhou HX, Szabo A, Eaton WA, Henry ER. *Proc.Natl.Acad.Sci.U.S.A* 1993;90:9547–9551. [PubMed: 8415739]
113. Kholodenko Y, Gooding EA, Dou Y, Ikeda-Saito M, Hochstrasser RM. *Biochemistry* 1999;38:5918–5924. [PubMed: 10231545]
114. Ionascu D, Gruia F, Ye X, Yu A, Champion PM. 2005to be submitted
115. Agmon N, Hopfield JJ. *J.Chem.Phys* 1983;78:6947–6959.
116. Kuczera K, Lambry JC, Martin JL, Karplus M. *Proc.Natl.Acad.Sci.U.S.A* 1993;90:5805–5807. [PubMed: 8516332]
117. Franzen S. *Proc.Natl.Acad.Sci.U.S.A* 2002;99:16754–16759. [PubMed: 12477933]
118. Agmon N, Hopfield JJ. *J.Chem.Phys* 1983;79:2042–2053.
119. Nienhaus K, Deng PC, Kriegl JM, Nienhaus GU. *Biochemistry* 2003;42:9647–9658. [PubMed: 12911306]
120. Szabo A. *Proc.Natl.Acad.Sci.U.S.A* 1978;75:2108–2111. [PubMed: 276856]
121. Brucker EA, Olson JS, Phillips GN, Dou Y, Ikedasaito M. *J.Biol.Chem* 1996;271:25419–25422. [PubMed: 8810310]
122. Sage JT, Li PS, Champion PM. *Biochemistry* 1991;30:1237–1247. [PubMed: 1991103]
123. Quillin ML, Brantley RE, Johnson KA, Olson JS, Phillips GN. *FASEB J* 1992;6:A466.
124. Hoffman BM, Petering DH. *PNAS* 1970;67:637–643. [PubMed: 4331717]
125. Liang J, Edelsbrunner H, Fu P, Sudhakar PV, Subramaniam S. *Proteins* 1998;33:18–29. [PubMed: 9741841]
126. Yu A, et al. 2005to be published
127. Schotte F, Lim M, Jackson TA, Smirnov AV, Soman J, Olson JS, Phillips GN Jr, Wulff M, Anfinrud PA. *Science* 2003;300:1944–1947. [PubMed: 12817148]
128. Bourgeois D, Vallone B, Schotte F, Arcovito A, Miele AE, Sciara G, Wulff M, Anfinrud P, Brunori M. *Proc.Natl.Acad.Sci.U.S.A* 2003;100:8704–8709. [PubMed: 12847289]
129. Hummer G, Schotte F, Anfinrud PA. *Proc.Natl.Acad.Sci.U.S.A* 2004;101:15330–15334. [PubMed: 15489270]
130. Srajer V, Teng TY, Ursby T, Perman B, Bourgeois D, Pradervand C, Schotte F, Kort R, Ren Z, Royer W, Hellingwerf K, Wulff M, Moffat K. *Abstracts Of Papers Of The American Chemical Society* 1998;216:390-HYS.
131. Srajer V, Ren Z, Teng TY, Schmidt M, Ursby T, Bourgeois D, Pradervand C, Schildkamp W, Wulff M, Moffat K. *Biochemistry* 2001;40:13802–13815. [PubMed: 11705369]
132. Zhu LY, Sage JT, Champion PM. *Biochemistry* 1993;32:11181–11185. [PubMed: 8218181]
133. Zhu L, Sage JT, Rigos AA, Morikis D, Champion PM. *J.Mol.Biol* 1992;224:207–215. [PubMed: 1548699]

134. Lim M, Jackson TA, Anfinrud PA. *Science* 1995;269:962–966. [PubMed: 7638619]
135. Sage JT. *Journal Of Biological Inorganic Chemistry* 1997;2:537–543.
136. Miller LM, Pedraza AJ, Chance MR. *Biochemistry* 1997;36:12199–12207. [PubMed: 9315857]
137. Kim S, Jin G, Lim M. *J.Phys.Chem.B* 2004;108:20366–20375.

Figure 1. MbNO Temperature dependent NO recombination dynamics to myoglobin after photolysis. The MEM inverse rate distributions along with the time evolution of the sample absorption change are shown for clarity on a double logarithmic scale. The MEM amplitudes are measured linearly on the right axis. Vertical and horizontal arrows indicate the kinetics tendency and the “slow” phase tendency, respectively, as the temperature is lowered from 290 K to 40 K. The left panel demonstrates the anomalous temperature dependent behavior where the recombination process is speeding up as the temperature is lowered towards 210 K.

Figure 2.

MbNO The upper panel presents the natural logarithm of MEM extracted rates as a function of inverse temperature (Arrhenius plot $\ln(k)$ vs. $1/T$) along with the corresponding rate amplitudes (lower panel). The barrier associated with the slow process (triangles) is found to be $3.0 \pm 1 \text{ kJ/mol}$. The fast process is found to be independent of temperature with no barrier. The upper panel inset resolves the temperature region between 290 K to 220 K (dashed rectangle) in which the recombination becomes faster as the temperature is lowered. The developed barrier at 290 K is found to be 0.57 kJ/mol.

Figure 3.

NO recombination dynamics to wtMb, swMb, hhMb, Mb(V68F) and Mb(V68W) mutants in aqueous buffer (left panel) and 75% glycerol buffer(right panel).. The MEM amplitudes are measured linearly on the right scale. Noteworthy is the relatively dramatic slow phase amplitude decrease that appears when the samples are studied using the glycerol based solvent or mutated.

Figure 4. Mb(V68W)NO mutant. Temperature dependent NO molecule recombination following photolysis of Mb(V68W)NO in glycerol (75%) based buffer plotted along with the corresponding maximum entropy distribution.

Figure 5.

Mb(V68W)NO. $\ln(k)$ vs. $1/T$ (upper panel) and the corresponding mem rate amplitudes as a function of temperature (lower panel). The upper panel inset resolves the temperature region between 290 K to 220 K (dashed rectangle) in which the recombination becomes faster as the temperature is lowered. The developed barrier at 290 K is calculated to be 0.64 kJ/mol. The rate amplitudes show no change over the studied temperatures (lower panel).

Figure 6. PPIX(NO) Temperature dependence of NO molecule recombination following photolysis of PPIX-NO in 80% (v/v) glycerol solution plotted on a log-log scale along with the corresponding maximum entropy distribution.

Figure 7. PPIX(NO) The plot of the $\ln(k)$ against inverse temperature. The inset resolves temperatures from 290 K to 90 K revealing a barrier of 0.32 kJ/mol. The lower panel shows the rate amplitudes to be constant over all the studied temperature range.

Figure 8.

The absorbance spectra before and after the photolysis of the MbNO and PPIXNO at room temperature are presented. The inset shows the MbNO transient difference spectra at different times. The spectra demonstrate the photolysis induced formation of five- coordinated iron species (histidine ligated deoxy Mb) at 435 nm with no sign of a bleach at 390 nm characteristic of the PPIXNO system in the absence of a histidine ligand. The blue and red circles depict the renormalized equilibrium difference spectrum of Mb and MbNO, which is well approximated by the transient difference.

Figure 9.

The harpoon model for NO binding where the unpaired NO electron and the electron in the dz^2 iron orbital can form a transition state without needing thermal fluctuations to drive the iron into the heme plane. Two different protein/heme conformations are shown and, since the NO “reaches in” and binds to either conformation with the same propensity, the ensemble yields a fast exponential kinetic response. The NO rebinding to iron is fast because the reaction does not need to overcome the heme barrier associated with moving the iron to the in-plane position. In contrast, the CO needs to wait for thermal fluctuations to drive the heme into the planar conformation so that the reaction can occur. As a result, the different initial protein/heme conformations within the ensemble (shown in the lower panels as dashed lines) lead to different enthalpic barriers to reach the common transition state (shown in the lower panels as the planar heme with solid lines). The kinetics in this case will be slower and (when the transition time between the initial conformational substates is slower than the rebinding time scale) non-exponential.

Figure 10.

(a) The extended distal pocket of the MbNO is depicted. (b) The homogeneous NO recombination scheme where the photolyzed NO molecule initially partitions into two subpopulations associated with states B and X. The state Mb** denotes the initial optically excited heme and the dashed arrows denote the bifurcation of the hot [NO]* fragment into states B and X. The notation Mb* denotes the unrelaxed protein following photolysis. Panels (c) shows the dependence of the NO recombination to Mb upon the pump and probe energy. Note the slow amplitude decrease as the pump wavelength is increased (decrease in energy) from 400 nm to 580 nm.

Scheme I.

Scheme II.

Table 1
Kinetic fitting parameters for selected hemes and heme proteins

Sample	Fast phase				Slow phase			
	T=290 K $k(s^{-1})$ τ (ps) Amplitude (%)	T=220 K $k(s^{-1})$ τ (ps) Amplitude (%)	Relaxation Barrier (kJ/mol) $-2.42 \ln[k_{290K}/k_{220K}]$	Arrhenius Barrier (kJ/mol)	T=290 K $k(s^{-1})$ τ (ps) Amplitude (%)	T=220 K $k(s^{-1})$ τ (ps) Amplitude (%)	Relaxation Barrier (kJ/mol) $-2.42 \ln[k_{290K}/k_{220K}]$	Arrhenius Barrier (kJ/mol)
MbNO (80% gly)	6.71×10^{10} 14.9 66%	8.47×10^{10} 11.8 70%	0.57	0±0.2	7.08×10^9 141.2 33%	9.33×10^9 107.2 30%	0.67	3±1
(V68F)NO (75% gly)	8.70×10^{10} 11.5 88%				1.10×10^{10} 91.2 12%			
(V68W)NO (80% gly)	8.93×10^{10} 11.2 99%	1.16×10^{11} 8.6 99%	0.64	0±0.2				
PPIX-NO (80% gly) no Imidazole	1.30×10^{11} 7.7 99%	1.23×10^{11} 8.1 99%		0.32 ± 0.1				
MbNO (water)	7.04×10^{10} 14.2 40%				6.25×10^9 160.0 60%			

* the experimental error in determining the time constant τ and its corresponding amplitude is estimated to be less than 4%

Table 2
Probe wavelength dependent rebinding amplitudes for MbNO

λ_{pump}	$\lambda_{\text{probe}} = 420 \text{ nm}$			$\lambda_{\text{probe}} = 438 \text{ nm}$			$\langle \lambda_{\text{probe}} \rangle$
	τ_i (ps)	A_i	τ_i (ps)	A_i	$\langle \tau_i \rangle$ (ps)	$\langle A_i \rangle$	
400 nm	13.8 200	0.41 0.59	13 190	-0.35 -0.65	13.4 195	0.38 0.62	
580 nm	8 170	0.6 0.4	8.3 170	-0.5 -0.5	8.2 170	0.55 0.45	